Compare ACCL & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACCL | MDXH |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | Hong Kong | Belgium |
| Employees | 22 | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 21.1M |
| IPO Year | N/A | 2021 |
| Metric | ACCL | MDXH |
|---|---|---|
| Price | $1.78 | $0.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 26.1K | ★ 786.3K |
| Earning Date | 05-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | $17.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.23 | $0.40 |
| 52 Week High | $5.00 | $5.33 |
| Indicator | ACCL | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 63.17 | 33.26 |
| Support Level | $1.30 | N/A |
| Resistance Level | $1.82 | $3.79 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 100.00 | 47.66 |
Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.